<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BostonU_Composite_Part skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BostonU/Composite Part</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV style="width:100%; background-color: grey;"><DIV id="table"><UL id="ulist"><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Attributions" class="dropbtn" id="onecon"><B>ATTRIBUTIONS</B></A><DIV class="dropdown-content"><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions">Team</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#adv">Advisors</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#pi">PIs</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#spon">Sponsors</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#support">Misc Support</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Medal_Criteria" class="dropbtn" id="twocon"><B>JUDGING</B></A><DIV class="dropdown-content"><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Medal_Criteria">Medal Criteria</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Engagement">Best Education &amp; Public Engagement</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Basic_Part">Best New Basic Part</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Composite_Part">Best New Composite Part</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Part_Collection">Best Part Collection</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/HP/Silver" class="dropbtn" id="threecon"><B>HUMAN PRACTICES</B></A><DIV class="dropdown-content"><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Silver">Intellectual Property Blog</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Gold">Bioethics Forums</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Tours">Industry Visits</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Collaborations">Collaborations</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Interlab">Interlab Study</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Safety">Safety</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Abstract_and_Motivation" class="dropbtn" id="fourcon"><B>PROJECT</B></A><DIV class="dropdown-content"><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Abstract_and_Motivation">Motivation</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Design">Design</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Proof">Proof of Concept</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Parts">Submitted Parts</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Description">Improved Part Characterization</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Notebook">Notebook</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU" class="dropbtn" id="fivecon" style="height:75px;"><B>HOME</B></A></LI><DIV class="column full_size"><DIV style="font-size:300%; padding:75px 50px 3px 50px; text-align:center; color:#0071A7;">Best New Composite Part</DIV><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
To create the Gemini parts library we made use of two “classes” of plasmid: guide RNA expressing vectors and guide RNA operator reporter vectors. When these two plasmids are co-transfected with a dCas9-VPR plasmid into a mammalian cell line, a gene of interest is expressed. Our work for iGEM dealt with fluorescent proteins; specifically, GFP for the parts submitted to the registry.  </P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
The guide RNA operator vector can be considered a composite part. It is constructed by combining the following basic parts in order: <A href="http://parts.igem.org/Part:BBa_K1875009" style="color:blue;">BBa_K1875009</A> (20 bp target sequence), <A href="http://parts.igem.org/Part:BBa_K1875000" style="color:blue;">BBa_K1875000</A> (minimal CMV promoter), <A href="http://parts.igem.org/Part:BBa_K1875001" style="color:blue;">BBa_K1875001</A> (Kozak sequence), <A href="http://parts.igem.org/Part:BBa_K1875003" style="color:blue;">BBa_K1875003</A> (GFP), <A href="http://parts.igem.org/Part:BBa_K1875002" style="color:blue;">BBa_K1875002</A> (Rabbit Beta Globin PolyA terminator). The sources of these parts can be found on their respective registry pages. </P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
We have submitted <A href="http://parts.igem.org/Part:BBa_K1875018" style="color:blue;">BBa_K1875018</A> for best composite part due to both its high expression and consistency in experimentation. This particular composite part has a triple multimerized operator for gRNA 13 (g13), meaning that there are three 20 bp target sequences for g13 (each separated by 24 random bases) upstream of the minimal CMV promoter. Through our experimentation, we identified that this part, when compared with a full-length CMV promoter, can actually express GFP at a higher level than the strong constitutive promoter. This means that this synthetic composite part enables even higher protein production compared to a natural promoter, and can be used usefully in many protein production applications. Additionally, because its activity is controlled by expression of a specific corresponding gRNA (g13), it can grant temporal control over protein expression.
 </P></DIV></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>